Clinical data of IFN-α– and imatinib-treated patients in chronic phase of CML
| Patient . | Sex . | Type of treatment . | Transcript . | Treatment period (mo) . | MRD* . | Response Type† . |
|---|---|---|---|---|---|---|
| UPN 6 | M | IFN-α | b2a2 | 17 | 3.9 | MR |
| UPN 7 | M | IFN-α | b2a2 | 51 | 0.54 | CR |
| UPN 8 | F | IFN-α | b3a2 | 39 | 0.27 | CR |
| UPN 9 | F | IFN-α | b3a2 | 11 | 3.2 | CR |
| UPN 10 | F | IFN-α | b3a2/b2a2 | 48 | 0.04 | CR |
| UPN 11 | M | IFN-α | b2a2 | 26 | NA | MR |
| UPN 12 | F | IFN-α | b3a2/b2a2 | 5 | NA | MR |
| UPN 13 | M | IFN-α | b3a2 | 78 | 0.01 | CR |
| UPN 1 | F | Imatinib | b2a2 | 3 | 2.1 | CR |
| UPN 2 | M | Imatinib | b3a2 | 3 | 3.8 | CR |
| UPN 3 | M | Imatinib | b2a2 | 3 | 15.0 | MR |
| UPN 4 | M | Imatinib | b2a2 | 3 | 6.4 | MinR |
| UPN 5 | F | Imatinib | b3a2 | 3 | 1.1 | CR |
| Patient . | Sex . | Type of treatment . | Transcript . | Treatment period (mo) . | MRD* . | Response Type† . |
|---|---|---|---|---|---|---|
| UPN 6 | M | IFN-α | b2a2 | 17 | 3.9 | MR |
| UPN 7 | M | IFN-α | b2a2 | 51 | 0.54 | CR |
| UPN 8 | F | IFN-α | b3a2 | 39 | 0.27 | CR |
| UPN 9 | F | IFN-α | b3a2 | 11 | 3.2 | CR |
| UPN 10 | F | IFN-α | b3a2/b2a2 | 48 | 0.04 | CR |
| UPN 11 | M | IFN-α | b2a2 | 26 | NA | MR |
| UPN 12 | F | IFN-α | b3a2/b2a2 | 5 | NA | MR |
| UPN 13 | M | IFN-α | b3a2 | 78 | 0.01 | CR |
| UPN 1 | F | Imatinib | b2a2 | 3 | 2.1 | CR |
| UPN 2 | M | Imatinib | b3a2 | 3 | 3.8 | CR |
| UPN 3 | M | Imatinib | b2a2 | 3 | 15.0 | MR |
| UPN 4 | M | Imatinib | b2a2 | 3 | 6.4 | MinR |
| UPN 5 | F | Imatinib | b3a2 | 3 | 1.1 | CR |
NA indicates not available.
MRD quantified as the ratio of BCR/ABL toABL transcripts. For IFN-α–treated patients (patients 6 through 13), the mean MRD ± standard error of the mean (SEM) was 1.32 ± 0.71. For imatinib-treated patients (patients 1 through 5), it was 5.68 ± 2.49.
Responses defined as complete cytogenetic response (CR, 0% of metaphase cells positive for the Philadelphia chromosome [Ph+]); major response (MR, < 35% Ph+); minor response (MinR, 35% to 94% Ph+).